- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting KRAS in pancreatic cancer: new drugs on the horizon
Authors
Keywords
-
Journal
CANCER AND METASTASIS REVIEWS
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-09-09
DOI
10.1007/s10555-021-09990-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- KRAS drives immune evasion in a genetic model of pancreatic cancer
- (2021) Irene Ischenko et al. Nature Communications
- Searching for treatments for non-G12C-KRAS mutant cancers
- (2021) Christina Guo et al. BRITISH JOURNAL OF CANCER
- Mutant KRAS drives metabolic reprogramming and autophagic flux in premalignant pancreatic cells
- (2021) Tatsunori Suzuki et al. CANCER GENE THERAPY
- The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy
- (2021) David M. Briere et al. MOLECULAR CANCER THERAPEUTICS
- Clinical acquired resistance to KRASG12C inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation
- (2021) Noritaka Tanaka et al. Cancer Discovery
- Bone marrow-derived macrophages converted into cancer-associated fibroblast-like cells promote pancreatic cancer progression
- (2021) Chika Iwamoto et al. CANCER LETTERS
- Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment
- (2021) D. Lucas Kerr et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Acquired Resistance to KRASG12C Inhibition in Cancer
- (2021) Mark M. Awad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interactions between Cancer-Associated Fibroblasts and T Cells in the Pancreatic Tumor Microenvironment and the Role of Chemokines
- (2021) Laia Gorchs et al. Cancers
- KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?
- (2020) Misako Nagasaka et al. CANCER TREATMENT REVIEWS
- Oncogenic Kras driven metabolic reprogramming in pancreas cancer cells utilizes cytokines from the tumor microenvironment
- (2020) Prasenjit Dey et al. Cancer Discovery
- Computational Prediction and Validation of Tumor-Associated Neoantigens
- (2020) Vladimir Roudko et al. Frontiers in Immunology
- Adoptive Cell Therapy Targeting Neoantigens: A Frontier for Cancer Research
- (2020) Zhidong Wang et al. Frontiers in Immunology
- Targeting the MAPK Pathway in KRAS-Driven Tumors
- (2020) Matthias Drosten et al. CANCER CELL
- Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer
- (2020) Jay B. Fell et al. JOURNAL OF MEDICINAL CHEMISTRY
- Tumor microenvironment remodeling enables bypass of oncogenic KRAS dependency in pancreatic cancer
- (2020) Pingping Hou et al. Cancer Discovery
- Immunotherapy for pancreatic cancer: A 2020 update
- (2020) Dimitrios Schizas et al. CANCER TREATMENT REVIEWS
- Discovery of Novel PDEδ Degraders for the Treatment of KRAS Mutant Colorectal Cancer
- (2020) Junfei Cheng et al. JOURNAL OF MEDICINAL CHEMISTRY
- RAS-targeted therapies: is the undruggable drugged?
- (2020) Amanda R. Moore et al. NATURE REVIEWS DRUG DISCOVERY
- The type of KRAS mutation drives PI3Kα/γ signalling dependency: Implication for the choice of targeted therapy in pancreatic adenocarcinoma patients
- (2020) Coralie Cayron et al. Clinics and Research in Hepatology and Gastroenterology
- Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs
- (2020) Michael J. Bond et al. ACS Central Science
- Post-translational modification of KRAS: potential targets for cancer therapy
- (2020) Wei-hua Wang et al. ACTA PHARMACOLOGICA SINICA
- Combinations with allosteric SHP2 inhibitor TNO155 to block receptor tyrosine kinase signaling
- (2020) Huai-Xiang Hao et al. CLINICAL CANCER RESEARCH
- mRNA vaccine–induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer
- (2020) Gal Cafri et al. JOURNAL OF CLINICAL INVESTIGATION
- SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling
- (2020) Carmine Fedele et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer
- (2020) Matthew J. LaMarche et al. JOURNAL OF MEDICINAL CHEMISTRY
- BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition
- (2020) Marco H Hofmann et al. Cancer Discovery
- GTP-State-Selective Cyclic Peptide Ligands of K-Ras(G12D) Block Its Interaction with Raf
- (2020) Ziyang Zhang et al. ACS Central Science
- Generation of KS-58 as the first K-Ras(G12D)-inhibitory peptide presenting anti-cancer activity in vivo
- (2020) Kotaro Sakamoto et al. Scientific Reports
- SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors
- (2019) Tamer A. Ahmed et al. Cell Reports
- Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction
- (2019) Roman C. Hillig et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer
- (2019) Christopher J. Halbrook et al. Cell Metabolism
- Understanding Cell Penetration of Cyclic Peptides
- (2019) Patrick G. Dougherty et al. CHEMICAL REVIEWS
- The effects and the mechanisms of autophagy on the cancer-associated fibroblasts in cancer
- (2019) Yuanliang Yan et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Sequential Targeting TGF‐β Signaling and KRAS Mutation Increases Therapeutic Efficacy in Pancreatic Cancer
- (2019) Yuanyuan Pei et al. Small
- Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer
- (2019) Thomas B. Karasic et al. JAMA Oncology
- Dual farnesyl and geranylgeranyl transferase inhibitor thwarts mutant KRAS-driven patient-derived pancreatic tumors
- (2019) Aslamuzzaman Kazi et al. CLINICAL CANCER RESEARCH
- Deoxycytidine Release from Pancreatic Stellate Cells Promotes Gemcitabine Resistance
- (2019) Simona Dalin et al. CANCER RESEARCH
- Development of targeted protein degradation therapeutics
- (2019) Philip P. Chamberlain et al. Nature Chemical Biology
- KRAS-Driven Metabolic Rewiring Reveals Novel Actionable Targets in Cancer
- (2019) Emanuela Pupo et al. Frontiers in Oncology
- Vertical pathway inhibition overcomes adaptive feedback resistance to KRASG12C inhibition
- (2019) Meagan B. Ryan et al. CLINICAL CANCER RESEARCH
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- (2019) Jude Canon et al. NATURE
- Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer
- (2019) G. Aaron Hobbs et al. Cancer Discovery
- The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
- (2019) Jill Hallin et al. Cancer Discovery
- Genetic landscape of prognostic value in pancreatic ductal adenocarcinoma microenvironment
- (2019) Ning Pu et al. Annals of Translational Medicine
- Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor
- (2018) Matthew R. Janes et al. CELL
- Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
- (2018) Dietrich A. Ruess et al. NATURE MEDICINE
- Ras-Mediated Activation of the Raf Family Kinases
- (2018) Elizabeth M. Terrell et al. Cold Spring Harbor Perspectives in Medicine
- Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma
- (2018) Zhi Rong Qian et al. JAMA Oncology
- RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers
- (2018) Robert J. Nichols et al. NATURE CELL BIOLOGY
- SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models
- (2018) Carmine Fedele et al. Cancer Discovery
- Cancer Neoantigens
- (2018) Ton N. Schumacher et al. Annual Review of Immunology
- Targeting the α4–α5 dimerization interface of K-RAS inhibits tumor formation in vivo
- (2018) Imran Khan et al. ONCOGENE
- Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes
- (2018) Andrew McGuigan et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
- (2017) Ugur Sahin et al. NATURE
- An immunogenic personal neoantigen vaccine for patients with melanoma
- (2017) Patrick A. Ott et al. NATURE
- Inhibition of mTORC2 component RICTOR impairs tumor growth in pancreatic cancer models
- (2017) Katharina M. Schmidt et al. Oncotarget
- Nucleotide based covalent inhibitors of KRas can only be efficient in vivo if they bind reversibly with GTP-like affinity
- (2017) Matthias P. Müller et al. Scientific Reports
- mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer
- (2016) David R. Driscoll et al. CANCER RESEARCH
- Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation
- (2016) Christopher J. Tape et al. CELL
- The Significance of Ras Activity in Pancreatic Cancer Initiation
- (2016) Craig D. Logsdon et al. International Journal of Biological Sciences
- Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions
- (2016) Paul A. Jackson et al. JOURNAL OF MEDICINAL CHEMISTRY
- How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization
- (2016) Ethan J. Brock et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion
- (2016) Cristovão M. Sousa et al. NATURE
- Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
- (2016) Ying-Nan P. Chen et al. NATURE
- Genomic analyses identify molecular subtypes of pancreatic cancer
- (2016) Peter Bailey et al. NATURE
- Inhibition of RAS function through targeting an allosteric regulatory site
- (2016) Russell Spencer-Smith et al. Nature Chemical Biology
- Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
- (2016) Jonathan M. L. Ostrem et al. NATURE REVIEWS DRUG DISCOVERY
- T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
- (2016) Eric Tran et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sos1 disruption impairs cellular proliferation and viability through an increase in mitochondrial oxidative stress in primary MEFs
- (2016) P Liceras-Boillos et al. ONCOGENE
- KRAS-related proteins in pancreatic cancer
- (2016) Karen M. Mann et al. PHARMACOLOGY & THERAPEUTICS
- Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
- (2016) P. Lito et al. SCIENCE
- Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State
- (2016) M. P. Patricelli et al. Cancer Discovery
- Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism
- (2016) Hongyun Zhao et al. eLife
- KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma
- (2016) Barbara Bournet et al. Clinical and Translational Gastroenterology
- Ras activation revisited: role of GEF and GAP systems
- (2015) Anne Hennig et al. BIOLOGICAL CHEMISTRY
- Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers
- (2015) Sheng-Bin Peng et al. CANCER CELL
- Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations
- (2015) J. C. Hunter et al. MOLECULAR CANCER RESEARCH
- Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2
- (2015) H. P. Soares et al. MOLECULAR CANCER THERAPEUTICS
- Whole genomes redefine the mutational landscape of pancreatic cancer
- (2015) Nicola Waddell et al. NATURE
- Allelic Ratio of KRAS Mutations in Pancreatic Cancer
- (2015) J. K. Lennerz et al. ONCOLOGIST
- A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
- (2015) B. M. Carreno et al. SCIENCE
- Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
- (2015) Agnieszka K. Witkiewicz et al. Nature Communications
- Pancreatic Adenocarcinoma
- (2015) David P. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ral small GTPase signaling and oncogenesis: More than just 15minutes of fame
- (2014) Leanna R. Gentry et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
- (2014) Andrew D. Rhim et al. CANCER CELL
- Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy
- (2014) Mara H. Sherman et al. CELL
- Phase II and Pharmacodynamic Study of Autophagy Inhibition Using Hydroxychloroquine in Patients With Metastatic Pancreatic Adenocarcinoma
- (2014) B. M. Wolpin et al. ONCOLOGIST
- The Dual RAF/MEK Inhibitor CH5126766/RO5126766 May Be a Potential Therapy for RAS-Mutated Tumor Cells
- (2014) Makoto Wada et al. PLoS One
- Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange
- (2014) Michael C. Burns et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Recombinant expression of different mutant K-ras gene in pancreatic cancer Bxpc-3 cells and its effects on chemotherapy sensitivity
- (2014) TengFei Shao et al. Science China-Life Sciences
- BRAF Inhibitors Induce Metastasis in RAS Mutant or Inhibitor-Resistant Melanoma Cells by Reactivating MEK and ERK Signaling
- (2014) B. Sanchez-Laorden et al. Science Signaling
- KRAS: feeding pancreatic cancer proliferation
- (2014) Kirsten L. Bryant et al. TRENDS IN BIOCHEMICAL SCIENCES
- Dosage-Dependent Regulation of Pancreatic Cancer Growth and Angiogenesis by Hedgehog Signaling
- (2014) Esha Mathew et al. Cell Reports
- Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity
- (2013) Nobuya Ishii et al. CANCER RESEARCH
- Targeting the RAS oncogene
- (2013) Asami Takashima et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Metabolic Alterations in Lung Cancer–Associated Fibroblasts Correlated with Increased Glycolytic Metabolism of the Tumor
- (2013) Virendra K. Chaudhri et al. MOLECULAR CANCER RESEARCH
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
- (2013) Jonathan M. Ostrem et al. NATURE
- Oncogenic K-Ras requires activation for enhanced activity
- (2013) H Huang et al. ONCOGENE
- Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment
- (2013) X Sui et al. Cell Death & Disease
- EGF Receptor Signaling Is Essential for K-Ras Oncogene-Driven Pancreatic Ductal Adenocarcinoma
- (2012) Carolina Navas et al. CANCER CELL
- EGF Receptor Is Required for KRAS-Induced Pancreatic Tumorigenesis
- (2012) Christine M. Ardito et al. CANCER CELL
- A Comprehensive Survey of Ras Mutations in Cancer
- (2012) I. A. Prior et al. CANCER RESEARCH
- Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism
- (2012) Haoqiang Ying et al. CELL
- Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers
- (2012) S. Dogan et al. CLINICAL CANCER RESEARCH
- Presence of Somatic Mutations in Most Early-Stage Pancreatic Intraepithelial Neoplasia
- (2012) Mitsuro Kanda et al. GASTROENTEROLOGY
- An NF-κB pathway–mediated positive feedback loop amplifies Ras activity to pathological levels in mice
- (2012) Jaroslaw Daniluk et al. JOURNAL OF CLINICAL INVESTIGATION
- Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice
- (2012) Meredith A. Collins et al. JOURNAL OF CLINICAL INVESTIGATION
- Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer
- (2012) Takeshi Ogura et al. JOURNAL OF GASTROENTEROLOGY
- Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
- (2012) Nathan T. Ihle et al. JNCI-Journal of the National Cancer Institute
- Cotargeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer
- (2012) T. M. Williams et al. MOLECULAR CANCER THERAPEUTICS
- Metastatic Pancreatic Cancer Is Dependent on Oncogenic Kras in Mice
- (2012) Meredith A. Collins et al. PLoS One
- Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression
- (2011) Paolo Cirri et al. CANCER AND METASTASIS REVIEWS
- Pancreatic cancers require autophagy for tumor growth
- (2011) S. Yang et al. GENES & DEVELOPMENT
- The GDI-like solubilizing factor PDEδ sustains the spatial organization and signalling of Ras family proteins
- (2011) Anchal Chandra et al. NATURE CELL BIOLOGY
- Regulating the regulator: post-translational modification of RAS
- (2011) Ian M. Ahearn et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies
- (2010) Milind M Javle et al. BMC CANCER
- PIK3CA Mutation Uncouples Tumor Growth and Cyclin D1 Regulation from MEK/ERK and Mutant KRAS Signaling
- (2010) E. Halilovic et al. CANCER RESEARCH
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
- (2010) Sonja J. Heidorn et al. CELL
- Overexpression of Smoothened Activates the Sonic Hedgehog Signaling Pathway in Pancreatic Cancer-Associated Fibroblasts
- (2010) K. Walter et al. CLINICAL CANCER RESEARCH
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- Pancreatic Endocrine Tumors: Expression Profiling Evidences a Role for AKT-mTOR Pathway
- (2009) Edoardo Missiaglia et al. JOURNAL OF CLINICAL ONCOLOGY
- Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis
- (2009) H. Tian et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer
- (2008) Brian M. Wolpin et al. JOURNAL OF CLINICAL ONCOLOGY
- Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
- (2008) S. Jones et al. SCIENCE
- The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway
- (2007) Marie Dance et al. CELLULAR SIGNALLING
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started